Remove Heart Valves Remove Open-Heart Surgery Remove Technology
article thumbnail

Atrium Health Sanger Heart & Vascular Institute Performs Landmark Heart Valve Surgery

DAIC

milla1cf Mon, 06/10/2024 - 17:58 June 10, 2024 — Atrium Health Sanger Heart & Vascular Institute has successfully completed the first commercial tricuspid clip procedure in the Carolinas, performed in May at Atrium Health Carolinas Medical Center. The recent approval of the tricuspid clip device by the U.S.

article thumbnail

Abbott Announces FDA Approval of First-of-its-kind Device to Repair Leaky Tricuspid Heart Valve, TriClip

DAIC

Food and Drug Administration (FDA) approval of its TriClip, a first-of-its-kind device to repair leaky tricuspid heart valve, for which more than 1.6 The imaging sub-study was a novel assessment of the right side of the heart using cardiac CT and MRI before and after a tricuspid repair procedure. Abbott has announced U.S

Tricuspid 105
article thumbnail

MindMics Demonstrates Its In-ear Infrasonic Earbud Technology Shows Promise in Detection of Aortic Stenosis and Hearing Heart Murmurs

DAIC

reported results from a clinical study of revolutionary earbuds that use a new technology - In-ear Infrasonic Hemodynography to Detects Aortic Stenosis Murmur Before and After Transcatheter Aortic Valve Replacement (TAVR). milla1cf Tue, 12/26/2023 - 21:36 December 26, 2023 — MindMics, Inc.

article thumbnail

Henry Ford Health Heart Failure Patient First in Michigan to Receive Breakthrough Device

DAIC

Image courtesy of Henry Ford Health milla1cf Wed, 02/21/2024 - 19:07 February 21, 2024 — An 80-year-old woman from Frankenmuth, Michigan is the first Henry Ford Health structural heart disease patient—and the first ever in Michigan—to receive a new transcatheter heart valve device for treating severe tricuspid regurgitation.

article thumbnail

FDA Advisory Committee Votes in Favor of Abbott’s First-of-its-kind Triclip System to Treat People with a Leaky Tricuspid Heart Valve

DAIC

"Tricuspid regurgitation can put added strain on the heart and lead to other cardiovascular issues, which can significantly worsen a person's quality of life, but historically there have been few treatment options," said Lars Søndergaard , M.D.,

Tricuspid 102
article thumbnail

New Late-breaking Data from Medtronic Evolut Low Risk Trial Demonstrate Strong Clinical and Cost-effectiveness Benefits of TAVR Platform

DAIC

milla1cf Tue, 03/12/2024 - 16:48 March 12, 2024 — Medtronic plc , a global leader in healthcare technology, today announced two late-breaking data presentations on four-year outcomes from the Evolut Low Risk Trial. At Medtronic, we continue to emphasize that valve design matters. mmHg TAVR; 11.8

TAVR 52